SlideShare une entreprise Scribd logo
1  sur  25
Johnson + Johnson NYSE:  JNJ Recommendation: Buy Connor Gallery ,[object Object],[object Object],November 18, 2008 “Caring for the world, one person at a time”
Johnson + Johnson In 3 Sentences ,[object Object],[object Object],[object Object]
Johnson + Johnson Key Facts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],Johnson + Johnson ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],Johnson + Johnson ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Johnson + Johnson It Sells Itself ,[object Object],[object Object],[object Object]
Johnson + Johnson Goodwill: 1982 Tylenol Murders ,[object Object],[object Object],[object Object]
Johnson + Johnson Consumer Products CLEAN & CLEAR  AVEENO  BAND-AID  LISTERINE MOTRIN IB    JOHNSONS NEUTROGENA  PEPCID AC REMBRANDT SPLENDA SUDAFED TYLENOL
Johnson + Johnson Pharmaceutical Focuses and Drug Therapies Anti-infective Antipsychotic Cardiovascular Contraceptive Dermatology Gastrointestinal Immunology Neurology Pain management Virology Risperdal Invega Procit Floxin Concerta Ortho Evra
Johnson + Johnson Medical Devices and Diagnostics Circulatory disease management Orthopedic joint reconstruction and spinal care Wound care  Women’s health Minimally invasive surgical Blood glucose monitoring and insulin delivery Diagnostic products Disposable contact lenses
Johnson + Johnson World Health Care Spending ,[object Object],[object Object],[object Object],[object Object]
Johnson + Johnson Areas of Growth ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Johnson + Johnson Areas of Growth: Consumer ,[object Object],[object Object],[object Object]
Johnson + Johnson Areas of Growth: Pharmaceuticals ,[object Object],[object Object],[object Object]
Johnson + Johnson Areas of Growth: Medical ,[object Object],[object Object],[object Object]
Johnson + Johnson ,[object Object],[object Object],2007 Revenue Breakdown
Johnson + Johnson Growth Strategy ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Johnson + Johnson The Market - Qualitative Assessment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Johnson + Johnson 2001 Recession Performance
Johnson + Johnson Current Market Position
Johnson + Johnson Current Market Position: Pharmaceuticals Competitors: Merck, Eli-Lilly, Bristol-Meyer, Schering - Plough
Johnson + Johnson Current Market Position Pharmaceutical Index
Johnson + Johnson
Johnson + Johnson
Johnson + Johnson Summary ,[object Object],[object Object],[object Object],[object Object]

Contenu connexe

Tendances

SB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersSB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersPhRMA
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021PhRMA
 
Ethical & unethical pharma market
Ethical & unethical pharma marketEthical & unethical pharma market
Ethical & unethical pharma marketFaheem Siddiqui
 
ALXN Buy Recommendation
ALXN Buy RecommendationALXN Buy Recommendation
ALXN Buy RecommendationEric Ebersole
 
Henk Eleveld - Selling Sickness 2010
Henk Eleveld - Selling Sickness 2010Henk Eleveld - Selling Sickness 2010
Henk Eleveld - Selling Sickness 2010Gezonde scepsis
 
Direct to Consumer Advertising Presentation
Direct to Consumer Advertising PresentationDirect to Consumer Advertising Presentation
Direct to Consumer Advertising Presentationcstam
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018PhRMA
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021PhRMA
 
GetPersonalized! Pharma's perspective on the future, Claudia Karnbach
GetPersonalized! Pharma's perspective on the future, Claudia KarnbachGetPersonalized! Pharma's perspective on the future, Claudia Karnbach
GetPersonalized! Pharma's perspective on the future, Claudia KarnbachSitra / Hyvinvointi
 
Year Ahead Pharma Healthcare 2017
Year Ahead Pharma Healthcare 2017Year Ahead Pharma Healthcare 2017
Year Ahead Pharma Healthcare 2017jamiedavies12345
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access3GDR
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Anup Soans
 

Tendances (15)

SB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA votersSB 17 doesn't address most pressing issues for CA voters
SB 17 doesn't address most pressing issues for CA voters
 
Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021Prescription Medicines: Insulin Costs in Context January 2021
Prescription Medicines: Insulin Costs in Context January 2021
 
Ethical & unethical pharma market
Ethical & unethical pharma marketEthical & unethical pharma market
Ethical & unethical pharma market
 
ALXN Buy Recommendation
ALXN Buy RecommendationALXN Buy Recommendation
ALXN Buy Recommendation
 
Henk Eleveld - Selling Sickness 2010
Henk Eleveld - Selling Sickness 2010Henk Eleveld - Selling Sickness 2010
Henk Eleveld - Selling Sickness 2010
 
Direct to Consumer Advertising Presentation
Direct to Consumer Advertising PresentationDirect to Consumer Advertising Presentation
Direct to Consumer Advertising Presentation
 
Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018Prescription Medicines - Costs in Context - October 2018
Prescription Medicines - Costs in Context - October 2018
 
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
7 Drivers: Pharmaceutical Television Advertising - John G. Baresky
 
IFPMA Code of Practice 2012
IFPMA Code of Practice2012IFPMA Code of Practice2012
IFPMA Code of Practice 2012
 
Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021Prescription Medicines Costs in Context April 2021
Prescription Medicines Costs in Context April 2021
 
Issues facing dietary supplements
Issues facing dietary supplementsIssues facing dietary supplements
Issues facing dietary supplements
 
GetPersonalized! Pharma's perspective on the future, Claudia Karnbach
GetPersonalized! Pharma's perspective on the future, Claudia KarnbachGetPersonalized! Pharma's perspective on the future, Claudia Karnbach
GetPersonalized! Pharma's perspective on the future, Claudia Karnbach
 
Year Ahead Pharma Healthcare 2017
Year Ahead Pharma Healthcare 2017Year Ahead Pharma Healthcare 2017
Year Ahead Pharma Healthcare 2017
 
Pharma Pricing & Market Access
Pharma Pricing & Market AccessPharma Pricing & Market Access
Pharma Pricing & Market Access
 
Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan Unethical Practices in Pharma - Interesting Study from Pakistan
Unethical Practices in Pharma - Interesting Study from Pakistan
 

En vedette

Crisis Management Workshop
Crisis Management WorkshopCrisis Management Workshop
Crisis Management WorkshopTony Lentini
 
Johnson and johnson
Johnson and johnson Johnson and johnson
Johnson and johnson nazlee ahmed
 
Tylenol poisoning
Tylenol poisoningTylenol poisoning
Tylenol poisoningDk Louis
 
Presenting Tomorrow Know Tylenol!!
Presenting Tomorrow Know Tylenol!!Presenting Tomorrow Know Tylenol!!
Presenting Tomorrow Know Tylenol!!Courtney Elise
 
Tylenol, Toyota and & Vioxx
Tylenol, Toyota and & VioxxTylenol, Toyota and & Vioxx
Tylenol, Toyota and & VioxxSubhradeep Mitra
 
Case study of Mc Neil
Case study of Mc Neil Case study of Mc Neil
Case study of Mc Neil Hitesh M
 
Iwasiw ppts ch07_3_e
Iwasiw ppts ch07_3_eIwasiw ppts ch07_3_e
Iwasiw ppts ch07_3_estanbridge
 
Crisis management (Event Management and Corporate Communication)
Crisis management (Event Management and Corporate Communication)Crisis management (Event Management and Corporate Communication)
Crisis management (Event Management and Corporate Communication)Palvi Jaswal
 
Johnson & Johnson's Tylenol Crisis
Johnson & Johnson's Tylenol CrisisJohnson & Johnson's Tylenol Crisis
Johnson & Johnson's Tylenol CrisisSudhir Singh Rajput
 
Tylenol Rebound: The Rise, Fall and Rise of Tylenol
Tylenol Rebound: The Rise, Fall and Rise of TylenolTylenol Rebound: The Rise, Fall and Rise of Tylenol
Tylenol Rebound: The Rise, Fall and Rise of TylenolSomak Ghosh
 
Johnson and johnson and tylenol case study
Johnson and johnson and tylenol case studyJohnson and johnson and tylenol case study
Johnson and johnson and tylenol case studyRhit Srivastava
 

En vedette (16)

Crisis Management Workshop
Crisis Management WorkshopCrisis Management Workshop
Crisis Management Workshop
 
Johnson and johnson
Johnson and johnson Johnson and johnson
Johnson and johnson
 
Tylenol poisoning
Tylenol poisoningTylenol poisoning
Tylenol poisoning
 
Tylenol case
Tylenol case Tylenol case
Tylenol case
 
Ch02
Ch02Ch02
Ch02
 
Presenting Tomorrow Know Tylenol!!
Presenting Tomorrow Know Tylenol!!Presenting Tomorrow Know Tylenol!!
Presenting Tomorrow Know Tylenol!!
 
Tylenol, Toyota and & Vioxx
Tylenol, Toyota and & VioxxTylenol, Toyota and & Vioxx
Tylenol, Toyota and & Vioxx
 
Crisis Management
Crisis ManagementCrisis Management
Crisis Management
 
Case study of Mc Neil
Case study of Mc Neil Case study of Mc Neil
Case study of Mc Neil
 
Crisis management
Crisis managementCrisis management
Crisis management
 
Iwasiw ppts ch07_3_e
Iwasiw ppts ch07_3_eIwasiw ppts ch07_3_e
Iwasiw ppts ch07_3_e
 
Crisis management (Event Management and Corporate Communication)
Crisis management (Event Management and Corporate Communication)Crisis management (Event Management and Corporate Communication)
Crisis management (Event Management and Corporate Communication)
 
Johnson & Johnson's Tylenol Crisis
Johnson & Johnson's Tylenol CrisisJohnson & Johnson's Tylenol Crisis
Johnson & Johnson's Tylenol Crisis
 
Tylenol Rebound: The Rise, Fall and Rise of Tylenol
Tylenol Rebound: The Rise, Fall and Rise of TylenolTylenol Rebound: The Rise, Fall and Rise of Tylenol
Tylenol Rebound: The Rise, Fall and Rise of Tylenol
 
Johnson and johnson and tylenol case study
Johnson and johnson and tylenol case studyJohnson and johnson and tylenol case study
Johnson and johnson and tylenol case study
 
Build Features, Not Apps
Build Features, Not AppsBuild Features, Not Apps
Build Features, Not Apps
 

Similaire à Gallery Jnj

Johnson & Johnson
Johnson & Johnson Johnson & Johnson
Johnson & Johnson mortress
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnsonanand karki
 
Factors affecting Johnson and johnson
Factors affecting Johnson and johnsonFactors affecting Johnson and johnson
Factors affecting Johnson and johnsonDeepshree Sharma
 
Strategic Management project on Johnson & Johnson
Strategic Management project on Johnson & Johnson Strategic Management project on Johnson & Johnson
Strategic Management project on Johnson & Johnson Shobhita Dayal
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryEngr. Carlo Senica, MBA, CPSM
 
Neha sharma _ppt final PIBM
Neha sharma _ppt final PIBM Neha sharma _ppt final PIBM
Neha sharma _ppt final PIBM NehaSharma1940
 
89224053 study-case-j-j
89224053 study-case-j-j89224053 study-case-j-j
89224053 study-case-j-jhomeworkping4
 
Johnson & Johnson North America
Johnson & Johnson North AmericaJohnson & Johnson North America
Johnson & Johnson North AmericaPriyanka Gujral
 
Johnson & Johnson by sangram pisat
Johnson & Johnson by sangram pisatJohnson & Johnson by sangram pisat
Johnson & Johnson by sangram pisatSangram Pisat
 
2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research IndustryPhRMA
 
Wiekang Biotech Investor Presentation, June 2010
Wiekang Biotech Investor Presentation, June 2010Wiekang Biotech Investor Presentation, June 2010
Wiekang Biotech Investor Presentation, June 2010GeoInvesting LLC
 
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015Hannah Joy Stacy
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1sokraturk
 
Janssen full analysis.pptx
Janssen full analysis.pptxJanssen full analysis.pptx
Janssen full analysis.pptxMarina Ibrahim
 

Similaire à Gallery Jnj (20)

Johnson & Johnson
Johnson & Johnson Johnson & Johnson
Johnson & Johnson
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnson
 
J&J Finance Project - new
J&J Finance Project - newJ&J Finance Project - new
J&J Finance Project - new
 
Factors affecting Johnson and johnson
Factors affecting Johnson and johnsonFactors affecting Johnson and johnson
Factors affecting Johnson and johnson
 
Strategic Management project on Johnson & Johnson
Strategic Management project on Johnson & Johnson Strategic Management project on Johnson & Johnson
Strategic Management project on Johnson & Johnson
 
Johnson&Johnson
Johnson&JohnsonJohnson&Johnson
Johnson&Johnson
 
Strategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical IndustryStrategic Management presentation for a Pharmaceutical Industry
Strategic Management presentation for a Pharmaceutical Industry
 
Neha sharma _ppt final PIBM
Neha sharma _ppt final PIBM Neha sharma _ppt final PIBM
Neha sharma _ppt final PIBM
 
89224053 study-case-j-j
89224053 study-case-j-j89224053 study-case-j-j
89224053 study-case-j-j
 
Johnson & Johnson North America
Johnson & Johnson North AmericaJohnson & Johnson North America
Johnson & Johnson North America
 
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressedThe 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
 
Johnson & Johnson by sangram pisat
Johnson & Johnson by sangram pisatJohnson & Johnson by sangram pisat
Johnson & Johnson by sangram pisat
 
2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry2014 Profile: Biopharmaceutical Research Industry
2014 Profile: Biopharmaceutical Research Industry
 
Wiekang Biotech Investor Presentation, June 2010
Wiekang Biotech Investor Presentation, June 2010Wiekang Biotech Investor Presentation, June 2010
Wiekang Biotech Investor Presentation, June 2010
 
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015
Sales Management Term Project: Marketing Plan for Johnson and Johnson 2015
 
TERMPROJECT1
TERMPROJECT1TERMPROJECT1
TERMPROJECT1
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1
 
Janssen full analysis.pptx
Janssen full analysis.pptxJanssen full analysis.pptx
Janssen full analysis.pptx
 
MBA Project
MBA ProjectMBA Project
MBA Project
 
Pakistan Pharma Overview
Pakistan Pharma OverviewPakistan Pharma Overview
Pakistan Pharma Overview
 

Gallery Jnj

  • 1.
  • 2.
  • 3.
  • 4.
  • 5.
  • 6.
  • 7.
  • 8. Johnson + Johnson Consumer Products CLEAN & CLEAR AVEENO BAND-AID LISTERINE MOTRIN IB JOHNSONS NEUTROGENA PEPCID AC REMBRANDT SPLENDA SUDAFED TYLENOL
  • 9. Johnson + Johnson Pharmaceutical Focuses and Drug Therapies Anti-infective Antipsychotic Cardiovascular Contraceptive Dermatology Gastrointestinal Immunology Neurology Pain management Virology Risperdal Invega Procit Floxin Concerta Ortho Evra
  • 10. Johnson + Johnson Medical Devices and Diagnostics Circulatory disease management Orthopedic joint reconstruction and spinal care Wound care Women’s health Minimally invasive surgical Blood glucose monitoring and insulin delivery Diagnostic products Disposable contact lenses
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19. Johnson + Johnson 2001 Recession Performance
  • 20. Johnson + Johnson Current Market Position
  • 21. Johnson + Johnson Current Market Position: Pharmaceuticals Competitors: Merck, Eli-Lilly, Bristol-Meyer, Schering - Plough
  • 22. Johnson + Johnson Current Market Position Pharmaceutical Index
  • 25.

Notes de l'éditeur

  1. Viagra
  2. Googwill - 14.1 B Intangibles - 14.6 B PPE 14.1 B
  3. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.
  4. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.
  5. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.
  6. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.
  7. Europe 23% Asia 14% Western Hemisphere 8% Similar profit margins in each category relative to percentages
  8. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.
  9. Companies established in Latin America, Europe, Africa and Australia for more than 70 years, and in Asia for more than 50 years.